MOGAMULIZUMAB

Brand name:

• Poteligeo®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Cutaneous T-Cell Lymphoma (CTCL)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Minor submission)

Comment:

--

Submission sponsor:

Kyowa Kirin Australia Pty Ltd

Other PBAC consideration:

• MOGAMULIZUMAB

Submission received for:

November 2020 PBAC meeting

Opportunity for consumer comment:

Open 26/08/2020 and close 07/10/2020 (see PBS Website)

PBAC meeting:

Held on 04/11/2020

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---